LifeMine Therapeutics
Develops fungal genome-derived therapeutics for organ transplant rejection
$263MSeries D+Series E
Role not disclosedActivity from announced rounds
Develops fungal genome-derived therapeutics for organ transplant rejection
Building a unified robotics foundation model for controlling robots